SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
NCT ID: NCT00985725
Last Updated: 2021-06-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
143 participants
INTERVENTIONAL
2009-10-29
2011-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01436149
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01435759
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01436162
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
NCT01436175
A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder
NCT02919579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
SPD489
SPD489 (Lisdexamfetamine dimesylate)
Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
Placebo
Placebo
Matching placebo
oral, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPD489 (Lisdexamfetamine dimesylate)
Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
Matching placebo
oral, once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Valley Research Center
Imperial, California, United States
Pharmacology Research Center
Los Alamitos, California, United States
Excell Research
Oceanside, California, United States
Neuropsychiatric Resesarch Center of Orange County
Santa Ana, California, United States
Connecticut Clincal Research
Cromwell, Connecticut, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Amit Vijapura, MD
Jacksonville, Florida, United States
Scientific Clinical Research, Inc.
North Miami, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Atlanta Institute of Medicine & Research
Atlanta, Georgia, United States
Carman Research
Smyrna, Georgia, United States
Joliet Center for Clinical Research
Joliet, Illinois, United States
Capstone Clinical Research
Libertyville, Illinois, United States
Psychiatric Associates
Overland Park, Kansas, United States
AccelRx Research
Fall River, Massachusetts, United States
St. Charles Psychiatric Associates
Saint Charles, Missouri, United States
PsychCare Consultants Research
St Louis, Missouri, United States
Premier Psychiatric Research Institute, LLC
Lincoln, Nebraska, United States
Richmond Behavioral Associates
Staten Island, New York, United States
North Carolina Neuropsychiatry, PA
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Richard H. Weisler, MD, PA & Associates
Raleigh, North Carolina, United States
Patient Priority Clinical Sites, LLC
Cincinnati, Ohio, United States
Lehigh Center for Clinical Research
Allentown, Pennsylvania, United States
Paramount Clinical Research
Bridgeville, Pennsylvania, United States
Suburban Research Associates
Media, Pennsylvania, United States
FutureSearch Trials of Dallas, LP
Dallas, Texas, United States
Bayou City Resesarch, LTD
Houston, Texas, United States
Red Oak Psychiatry Associates, PA
Houston, Texas, United States
University Hills Clinical Research
Irving, Texas, United States
R/D Clinical Research, Inc.
Lake Jackson, Texas, United States
Wharton Research Center
Wharton, Texas, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Madhoo M, Keefe RS, Roth RM, Sambunaris A, Wu J, Trivedi MH, Anderson CS, Lasser R. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014 May;39(6):1388-98. doi: 10.1038/npp.2013.334. Epub 2013 Dec 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPD489-205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.